Rho related BTB domain containing 1Genealiases: []
Q-omics provides the consensus-scored RHOBTB1 profile across patient tissues and cancer cell-line models. RHOBTB1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHOBTB1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RHOBTB1 RNA expression shows 19,043 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where RHOBTB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOBTB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOBTB1 survival associations across molecular data types. RHOBTB1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOBTB1 RNA expression–survival associations across cancer types. High RHOBTB1 expression shows unfavorable associations in BLCA, MESO, ACC, LGG and CESC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHOBTB1 RNA expression.
This table summarizes RHOBTB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHOBTB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOBTB1 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, HNSC, COAD and CHOL. The KIRC box plot shows higher RHOBTB1 RNA expression in tumor versus normal tissue (log2 FC = +1.589, t-test p < 0.001).
This table shows molecular features associated with RHOBTB1 in patient tissues and cancer cell lines. In patient samples, RHOBTB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOBTB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
